Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 6.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,417,472 shares of the company’s stock after acquiring an additional 84,522 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.99% of Denali Therapeutics worth $32,913,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DNLI. PNC Financial Services Group Inc. raised its stake in Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after purchasing an additional 807 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Denali Therapeutics by 5.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after buying an additional 1,372 shares in the last quarter. Swiss National Bank raised its position in Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC boosted its position in Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after acquiring an additional 1,847 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Denali Therapeutics by 9.0% during the second quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after purchasing an additional 2,730 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a research note on Wednesday, September 4th. Bank of America upped their target price on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Citigroup lifted their price target on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wedbush dropped their price objective on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $28.67 on Wednesday. The business’s 50-day simple moving average is $25.56 and its 200-day simple moving average is $21.87. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $32.13. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of -29.86 and a beta of 1.37.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.09. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. During the same quarter last year, the business earned $1.30 EPS. The company’s revenue for the quarter was down 99.7% on a year-over-year basis. As a group, equities research analysts forecast that Denali Therapeutics Inc. will post -2.54 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.